A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

February 21, 2020

Primary Completion Date

April 7, 2027

Study Completion Date

April 7, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Daratumumab

Participants will receive daratumumab.

DRUG

Talquetamab

Participants will receive talquetamab.

DRUG

Teclistamab

Participants will receive teclistamab.

DRUG

Pomalidomide

Participants will receive pomalidomide.

Trial Locations (24)

10011

The Blavatnik Family Chelsea Medical Center at Mount Sinai, New York

10029

Mount Sinai Medical Center, New York

19104

University of Pennsylvania, Philadelphia

20246

Universitaetsklinikum Hamburg Eppendorf, Hamburg

27157

Wake Forest Baptist Medical Center, Winston-Salem

28040

Hosp Univ Fund Jimenez Diaz, Madrid

28204

Levine Cancer Institute, Charlotte

31008

Clinica Univ. de Navarra, Pamplona

37007

Hosp Clinico Univ de Salamanca, Salamanca

37232

Vanderbilt Ingram Cancer Center, Nashville

53226

Medical College Of Wisconsin, Milwaukee

69120

Universitaetsklinikum Heidelberg, Heidelberg

79106

Universitatsklinikum Freiburg, Freiburg im Breisgau

91010

City of Hope National Medical Center, Duarte

92618

City of Hope Orange County Lennar Foundation Cancer Center, Irvine

94143

University of California San Francisco, San Francisco

97080

Universitatsklinikum Wurzburg, Würzburg

T2N 5G2

Arthur J E Child Comprehensive Cancer Centre, Calgary

M5G 2M9

University Health Network UHN Princess Margaret Cancer Centre, Toronto

1081 HV

VU Medisch Centrum, Amsterdam

2333ZA

LUMC, Leiden

08036

Hosp Clinic de Barcelona, Barcelona

08908

Inst. Cat. Doncologia-H Duran I Reynals, Barcelona

08916

Germans Trias I Pujol, Barcelona

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY